Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Multiple Myeloma 1Mesothelioma, Malignant 1Melanoma 1Lymphoma, Large B-Cell, Diffuse 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Lobular 1

Interventions

Cisplatin 15Pemetrexed 12pembrolizumab 9Carboplatin 8Nivolumab 7Cyclophosphamide 6Platinum 5Ipilimumab 51,2-diaminocyclohexaneplatinum II citrate 5fludarabine 3Radiotherapy, Intensity-Modulated 3Interleukin-2 3Gemcitabine 3tremelimumab 2durvalumab 2atezolizumab 2aldesleukin 2Radiotherapy 2Radiation 2Photochemotherapy 2Pharmaceutical Preparations 2Methotrexate 2Drug Therapy 2Chemotherapy, Adjuvant 2Cerebral Decortication 2nintedanib 1methoxyamine 1decitabine and cedazuridine drug combination 1cemiplimab 1cediranib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mesothelioma, Malignant × Drugs, Generic × 1 year × Clear all
NCT04914897 2025-10-02

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)

Sanofi

Phase 2 Terminated
106 enrolled 21 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡